How to Cite
Abstract
Приведены данные литературы и собственные наблюдения о применении летрозола при раке яичников. Показана его эффективность у части больных с эстрогенрецептор-положительными опухолями. Обсуждены возможные показания к применению летрозола у больных раком яичников. Необходимы дальнейшие исследования для получения более определенных критериев назначения летрозола у этой категории больных.References
Максимов С.Я., Гусейнов К.Д. Таргетная терапия при раке яичников // Практ. онкол. - 2011. - Т. 11(4). - С. 267-273.
Baum M., Buzdar A.U., Cuzick J. et al. Anastrozole alone or in combination with tamoxifen versus Tamoxifen alone for adjuvanttreatment with erly breasr cancer: first results of ATAC randomized trial // Lancet. - 2002. - Vol. 359. - P. 2131-2139.
Bowman A., Gabra H., Langdon S.P. et al. CA 125 respons is associated with esrtrogen receptor Expression in a phase II trial of letrozole in ovarian cancer // Clin. Cancer Res. - 2002. - Vol. 8. - P. 2233-2239.
Faratian D., Zweemer A.J., Nagumo Y. et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies // Clin. Cancer Res. -2011. - Vol. 17(13). - P. 4451-4461.
Hatc K.D., Beecham J.B., Blessing J.A. et al. Responsiveness of patient with advanced ovarian cancer to tamoxifen // Cancer. - 1991. - Vol. 68. - P. 269-271.
Jemal A., Siegel K., Ward E. et al. Cancer statistics, 2008 // Ca: A cancer J. for clinicians. - 2008. - Vol. 58. - P. 71-96.
Kotharu R., Argenta P., Fowler. Et al. Antiestrogen therapy in recurent ovarian cancer in 28 months of stably disease: a case report and review of the literature // Arch Oncol. - 2010. - Vol. 18. - P. 32-35.
Kuhnel R., Dellemare J.F., Rao B.R., Stolk J.G. Corellation of aromatase activity and steroid receptors in human ovarian carcinoma // Anticancer Res. - 1986. Vol. 6. - P. P889-892.
Langdon S.P., Crew A.J., Ritchie A.A. Growth ingibition of estrogen receptor-positive humanovarian carcinoma by antiestrogens in vitro and in a xenograft model // Eur J Cancer. - 1994. - Vol. 30A. - P. 682-686.
Marth C., Sortheim N., Kaern J., Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma // Int. J Gynecol Cancer. - 1997. - Vol. 7. - P. 256-261.
Miller W.R. Biology of aromatase inhibitors: pharmacology / endocrinology within the breast // Endocr. Relat. Cancer. - 1999. - Vol. 6. - P. 187-195.
Mouridsen H., Gershanovich M., Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study for International Letrozole Breaste Cancer Group. // J Clin. Oncol. - 2001. - Vol. 19. - P. 2596-2606.
Pan Y., Kao M.S. Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case-report and literature review // Curr. Oncol. - 2010. - Vol. 17. - P. 82-85.
Papadimitriou C.A., Makaki S., Siapkaras J. et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study // Oncology. - 2004. - Vol. 66. - P. 112-117.
Ramirez R.T., Shemeler K.M., Milam M.R. et al. Efficacy of letrozole in the treatment of recurrent platinum and taxane - resistant high - grade cancer of the ovary or peritoneum // Gynecol. Oncol. - 2008. - Vol. 110. - P. 56-59.
Rustin G.J., Marples M., Nelstrop A.E. et al. Use of CA-125 to define progression of ovarian cancer in patients with persistlently elevated levels // J Clin Oncol. - 2001. - Vol. 19. - P. 4054-4057.
Smyth J.F., Gourley C., Walker G. et al. Antiestrogen terapy is active in selected ovarian cancercases: the use of letrozole in estrogen-receptor positive patients // Clin Cancer Res. - 2007. - Vol. 13. - P. 3617-3622.
Williams C.J. Tamoxifen in relapsed ovarian cancer: a systemic review // Int. J. Gynecol. Cancer. - 1998. - Vol. 8. - P. 89-94.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...